Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.

Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P

Diabetes care13 Sept 2018Cited by 35 (Europe PMC)

PMID30213882DOI10.2337/dc18-1091PepBankPUB-30213882

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide lowered mean glucose versus placebo with the same insulin regimen.
In plain wordsIn people with type 1 diabetes, pramlintide lowered mean glucose versus placebo with the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMean glucose by CGM
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Measurements
Mean glucose
8.5 mmol/L
Pramlintide
Mean glucose
9.7 mmol/L
Placebo
Source sentences
Summary
Mean 24-h glucose measured by CGM was lower with pramlintide versus placebo (8.5 vs. 9.7 mmol/L, respectively; P = 0.012) due to a marked reduction of postprandial increments.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388201
02HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced postprandial glucose increments versus placebo with the same insulin regimen.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucose increases after meals versus placebo with the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose increments
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Mean 24-h glucose measured by CGM was lower with pramlintide versus placebo (8.5 vs. 9.7 mmol/L, respectively; P = 0.012) due to a marked reduction of postprandial increments.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388202
03HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced glycemic variability versus placebo with the same insulin regimen.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucose variability versus placebo with the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlycemic variability
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Glycemic variability was reduced, and postprandial glucagon and triglycerides were also lower with pramlintide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388203
04HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide lowered postprandial glucagon versus placebo with the same insulin regimen.
In plain wordsIn people with type 1 diabetes, pramlintide lowered glucagon after meals versus placebo with the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Glycemic variability was reduced, and postprandial glucagon and triglycerides were also lower with pramlintide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388204
05HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide lowered postprandial triglycerides versus placebo with the same insulin regimen.
In plain wordsIn people with type 1 diabetes, pramlintide lowered triglycerides after meals versus placebo with the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial triglycerides
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Lipids · Metabolic and weight
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Glycemic variability was reduced, and postprandial glucagon and triglycerides were also lower with pramlintide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388205
06HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes, gastrointestinal side effects were more frequent with pramlintide than placebo under the same insulin regimen.
In plain wordsIn people with type 1 diabetes, gastrointestinal side effects were more frequent with pramlintide than placebo under the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGastrointestinal side effects
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Gastrointestinal side effects were more frequent during use of pramlintide; no major hypoglycemic events occurred with pramlintide or placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388206
07HumanRandomized controlled trialSafety outcome
In patients with type 1 diabetes, no major hypoglycemic events occurred with pramlintide or placebo under the same insulin regimen.
In plain wordsIn people with type 1 diabetes, no major hypoglycemic events occurred with pramlintide or placebo under the same insulin regimen.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMajor hypoglycemic events
Study
n: not reported in source
Comparator
Placebo with the same regular human insulin regimen
Outcome group
Adverse events · Metabolic and weight
Studied dose
9 μg/unit insulin · Infusion pump · 24 hAs given in this study (human).
Source sentences
Summary
Gastrointestinal side effects were more frequent during use of pramlintide; no major hypoglycemic events occurred with pramlintide or placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with type 1 diabetes were stabilized on insulin pump therapy with insulin lispro before a randomized, single-masked, two-way crossover, 24-h inpatient study
Summary · context
Meal content and timing and patient-specific insulin doses were the same with each treatment.
Report a problemFND-3021388207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1Results postedNCT02500979

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

AstraZenecan = 3417 Aug 2015 to 5 Aug 2016

Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 2 Nov 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.